Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026
Kelun-Biotech said the drug showed a manageable safety profile and early anti-tumor activity in 140 patients across dose levels.
- On Tuesday, June 2, 2026, Kelun-Biotech presented first-in-human study results for the B7-H3 ADC SKB500 at the American Society of Clinical Oncology Annual Meeting in Chicago.
- Professor Liu Haifeng from Jilin Provincial Cancer Hospital presented the findings as a rapid oral report, detailing how SKB500 targets advanced solid tumors, a major area of unmet medical need.
- Clinical results showed broad-spectrum anti-tumor activity, with patients receiving the 12 mg/kg dose exhibiting a more favorable safety profile than the 16 mg/kg group, demonstrating robust efficacy and manageable safety.
- Among treated extensive-stage small cell lung cancer patients, the objective response rate reached 54.1%, with investigators noting a low rate of permanent treatment discontinuation, laying a solid foundation for further clinical development.
- Representing one of several drug projects, SKB500 aligns with Kelun-Biotech's commitment to becoming a leading global enterprise and addressing critical gaps in cancer treatment.
28 Articles
28 Articles
Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026
CHENGDU, China, June 2, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, the first-in-human study results of the…
Kelun-Biotech presents first-in-human data for B7-H3 ADC SKB500 at ASCO 2026
CHENGDU, China, June 3, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (\"Kelun-Biotech\" or the \"Company\", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, the first-in-human study results of the novel B7-H3 ADC SKB500 in patients with advanced solid tumors were presented as a rapid oral report by Professor Liu Haifeng from Jilin Provincial Cancer Hos…
Coverage Details
Bias Distribution
- 81% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
